{
    "clinical_study": {
        "@rank": "48683", 
        "arm_group": {
            "arm_group_label": "ACTH Gel", 
            "arm_group_type": "Other", 
            "description": "Open label Adrenocorticotropic Hormone (ACTH) Gel for 12 weeks, 80u (1mL),  given subcutaneously twice each week."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this research study is to evaluate if the study drug, ACTH Gel helps decrease\n      the disease symptoms in people with Rheumatoid Arthritis (RA) who are already taking\n      medications prescribed by their physician and are still experiencing disease symptoms.\n\n      ACTH gel has been a Food and Drug Administration-approved treatment for Rheumatoid Arthritis\n      since 1952, and in 2010 the FDA retained RA as a disease approved for ACTH gel use. Despite\n      its FDA approval there is very limited data on its how well ACTH gel works in improving the\n      symptoms of people with RA."
        }, 
        "brief_title": "ACTH Gel Therapy in Rheumatoid Arthritis", 
        "completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Rheumatoid Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  18 year of age and older\n\n          -  RA diagnosis by American College of Rheumatology criteria\n\n          -  Active disease (CDAI > 10)\n\n          -  Have received at least are biologic agent for at least 6 months\n\n          -  May or may not be receiving oral daily steroids (less than or equal to 20 mg/day) of\n             prednisone equivalent\n\n          -  No current active infections requiring antibiotics\n\n          -  Patients must be on stable doses of RA therapies (e.g., methotrexate or other RA\n             therapies for at least 4 weeks prior to baseline visit)\n\n        Exclusion Criteria:\n\n          -  Less than 18 years of age\n\n          -  Unable or unwilling to give Informed Consent\n\n          -  Have an active infection requiring the use of antibiotics\n\n          -  Women who are pregnant\n\n          -  Uncontrolled hypertension\n\n          -  Abnormal renal function\n\n          -  Abnormal liver function as defined by and increased Alanine transaminase (ALT,) and\n             aspartate aminotransferase (AST) that is greater than 5 times normal."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 6, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02030028", 
            "org_study_id": "PRO13080577"
        }, 
        "intervention": {
            "arm_group_label": "ACTH Gel", 
            "intervention_name": "Adrenocorticotropic Hormone Gel (ACTH)", 
            "intervention_type": "Drug", 
            "other_name": "ACTHAR gel"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Adrenocorticotropic Hormone", 
                "Hormones", 
                "Beta-Endorphin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Rheumatoid Arthritis", 
            "ACTH gel"
        ], 
        "lastchanged_date": "January 6, 2014", 
        "location": {
            "contact": {
                "email": "mcbridedl@upmc.edu", 
                "last_name": "Dawn McBride, RN", 
                "phone": "412-648-9413"
            }, 
            "facility": {
                "address": {
                    "city": "Pittsburgh", 
                    "country": "United States", 
                    "state": "Pennsylvania", 
                    "zip": "15261"
                }, 
                "name": "University of Pittsburgh"
            }, 
            "investigator": {
                "last_name": "Larry W Moreland, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Open Label Study to Evaluate Efficacy and Safety of Short-Term, Adjunctive Adrenocorticotropic Hormone (ACTH) Gel in Rheumatoid Arthritis", 
        "overall_contact": {
            "email": "mcbridedl@upmc.edu", 
            "last_name": "Dawn McBride, RN", 
            "phone": "412-648-9413"
        }, 
        "overall_official": {
            "affiliation": "University of Pittsburgh", 
            "last_name": "Larry W Moreland, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "We propose a 20% improvement after 12 weeks of therapy compared to baseline as a positive response.", 
            "measure": "Changes in Clinical Disease Activity Index", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02030028"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Pittsburgh", 
            "investigator_full_name": "Dr. Larry W. Moreland", 
            "investigator_title": "Margaret J. Miller Endowed Professor of Arthritis Research, Professor of Medicine, Immunology, and Clinical and Translational Science; Chief, Division of Rheumatology and Clinical Immunology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "We expect an improvement in the disease activity score along with an improved C-Reactive protein value.", 
                "measure": "Change in the Disease Activity Score", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "We expect the erythrocyte sedimentation rate (ESR) and the C-reactive protein value  to improve.", 
                "measure": "Changes in acute phase reactants", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "We expect patient to report using the FACIT-F scoring tool to report improvement in their level of fatigue.", 
                "measure": "Patient reported changes in fatigue", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }
        ], 
        "source": "University of Pittsburgh", 
        "sponsors": {
            "collaborator": {
                "agency": "Questcor Pharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "University of Pittsburgh", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}